On the contrary, in non-inmunogenic endometrial cancer, recent studies have associated alterations such as CTNNB1 or PIK3CA genomic aberrations and CMYC amplification, with a low neoantigen load, that could lead to predict poor effects of immunotherapy response. This evidence concerns the gene CTNNB1 and endometrial cancer.